

FORM 7
August 2019
MONTHLY PROGRESS REPORT

Name of Listed Issuer: [EVIANA HEALTH CORPORATION](#) (the “Issuer”).

Trading Symbol: [EHC](#)

Number of Outstanding Listed Securities: [23,899,849](#)

Date: [October 8th, 2019](#)

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

During the month of August 2019, the Issuer completed the following milestones, through Opco (defined below):

The intended hemp sale to ICC as announced by the Company on February 25, 2019 has been terminated.

Due to the small extraction capacity with Vitalis CO2 extractor equipment, approximating 18 kg per day, and denial from the board for financing larger capacity extractor of at least 1,000kg per day, as was planned by the management in September 2018, and planned with funds from convertible debentures, management tried to find solution for stock of hemp.

On August 5th, 2019, Intiva Plus d.o.o., a Serbian subsidiary of the Company, sold and delivered 97,276kg of hemp inventory for 18 EUR per kg (1,750,968 EUR total) to Montenegro Bio Science d.o.o. with the purchase price payable in monthly 150,000 EUR instalments commencing not later than 60 days after the date of delivery.

Harvest of 35 hectares began during the mid of August with a lack of funding, causing workforce dissatisfaction and absence, along with not being able to purchase needed and agreed agricultural equipment for harvest season 2019.

2. Provide a general overview and discussion of the activities of management.

In August 2019, the Company continued to explore potential partnerships Management has been discussing two offers in August.

The first one is a proposed hostile take-over from AgraFlora, announced on August 9, 2019.

The second one is a proposed private placement and joint venture from Abrazen-Devolli, announced on August 26, 2019. Management has been meeting with investment bankers to advise on the potential transactions.

On August 30, 2019, the Company's CEO provided to the members of the Board a Contract for Co-operation (Extraction & Packaging LOI) to constitute a joint venture consisting of Galafarm Dooel and Hanf Pharma Skopje. Galafarm Skopje has GMP licence for extraction and formulation of final CBD products. This agreement is being discussed by management and is yet to be approved and ratified by the Board.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable in the current month.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable in the current month.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable in the current month.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable in the current month.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how

FORM 7 – MONTHLY PROGRESS REPORT

January 2015

Page 2

the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable in the current month.

8. Describe the acquisition of new customers or loss of customers.

Not applicable in the current month.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable in the current month.

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable in the current month.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable in the current month.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable in the current month.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable in the current month.

14. Provide details of any securities issued and options or warrants granted.

Not applicable in the current month.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾

(1) State aggregate proceeds and intended allocation of proceeds.

FORM 7 – MONTHLY PROGRESS REPORT

January 2015

15. Provide details of any loans to or by Related Persons.

During the month, the Issuer advanced \$0 to Opco. The total amount receivable from Opco is \$8,140,351 as at August 31, 2019.

16. Provide details of any changes in directors, officers or committee members.

Not applicable in the current month.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Not applicable in the current month.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated **October 8, 2019**

DR. AVRAM ADIZES

Name of Director or Senior
Officer

"Dr. Avram Adizes"

Signature

DIRECTOR/CEO

Official Capacity

<i>Issuer Details</i>	For Month End	Date of Report
Name of Issuer	August 2019	YY/MM/D
EVIANA HEALTH CORPORATION		19/10/8
Issuer Address		
5728 E. BOULEVARD		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
VANCOUVER, BC, V6M 4M4	()	(416) 369-9993

FORM 7 – MONTHLY PROGRESS REPORT

January 2015

Contact Name Avram Adizes	Contact Position CEO	Contact Telephone No. SAME AS ABOVE
Contact Email Address info@eviana.com	Web Site Address WWW.EVIANA.COM	

FORM 7 – MONTHLY PROGRESS REPORT

January 2015